Treatment options for urge incontinence

Caffeine reduction is the first recommended therapy for patients with significant urge incontinence and a history of excessive caffeine use. If symptoms persist, bladder training is the next step. For those who do not respond to bladder training, oxybutynin may be effective. In postmenopausal women with significant vaginal atrophy, oestrogen cream may also be tried. However, electrical stimulation is not routinely recommended. It is important to consult with a healthcare professional to determine the best treatment plan for individual cases of urge incontinence.

Antenatal care is an important aspect of pregnancy, and the National Institute for Health and Care Excellence (NICE) has issued guidelines on routine care for healthy pregnant women. The guidelines recommend 10 antenatal visits for first pregnancies and 7 visits for subsequent pregnancies, provided that the pregnancy is uncomplicated. Women do not need to see a consultant if their pregnancy is uncomplicated.

The timetable for antenatal visits begins with a booking visit between 8-12 weeks, where general information is provided on topics such as diet, alcohol, smoking, folic acid, vitamin D, and antenatal classes. Blood and urine tests are also conducted to check for conditions such as hepatitis B, syphilis, and asymptomatic bacteriuria. An early scan is conducted between 10-13+6 weeks to confirm dates and exclude multiple pregnancies, while Down’s syndrome screening is conducted between 11-13+6 weeks.

At 16 weeks, women receive information on the anomaly and blood results, and if their haemoglobin levels are below 11 g/dl, they may be advised to take iron supplements. Routine care is conducted at 18-20+6 weeks, including an anomaly scan, and at 25, 28, 31, and 34 weeks, where blood pressure, urine dipstick, and symphysis-fundal height (SFH) are checked. Women who are rhesus negative receive anti-D prophylaxis at 28 and 34 weeks.

At 36 weeks, presentation is checked, and external cephalic version may be offered if indicated. Information on breastfeeding, vitamin K, and ‘baby-blues’ is also provided. Routine care is conducted at 38 weeks, and at 40 weeks (for first pregnancies), discussion about options for prolonged pregnancy takes place. At 41 weeks, labour plans and the possibility of induction are discussed. The RCOG advises that either a single-dose or double-dose regime of anti-D prophylaxis can be used, depending on local factors.

A family history doesn’t pose any contraindications for COCP use and is classified as UKMEC 1. However, being a known BRCA1/2 gene carrier is classified as UKMEC 3 for COCP use. If a person has a current breast cancer diagnosis, it is classified as UKMEC 4. If the breast cancer diagnosis was more than 5 years ago, it is classified as UKMEC 3.

Contraindications for Combined Oral Contraceptive Pill

The decision to prescribe the combined oral contraceptive pill is based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential cautions and contraindications on a four-point scale. UKMEC 1 represents a condition for which there is no restriction for the use of the contraceptive method, while UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, immobility, and a family history of thromboembolic disease in first-degree relatives under 45 years old. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension.

In 2016, the UKMEC was updated to reflect that breastfeeding between 6 weeks and 6 months postpartum is now classified as UKMEC 2 instead of UKMEC 3. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. It is important for healthcare providers to consider these contraindications when deciding whether to prescribe the combined oral contraceptive pill to their patients.

Fibroids in Pregnancy

Fibroids are a common occurrence in pregnancy, with reported incidence rates varying depending on the method of diagnosis used. These growths are dependent on estrogen and may increase in size during pregnancy, leading to large for dates pregnancies. However, they can also be complicated by red degeneration, which occurs when the blood supply to the fibroid is compromised, resulting in pain and uterine tenderness. Treatment for this condition is expectant, with bed rest and analgesia being the primary methods used. Other complications that may arise include malpresentation, obstructed labor, and, in rare cases, postpartum hemorrhage. It is important for healthcare providers to be aware of these potential complications and to monitor patients with fibroids closely during pregnancy.

A lower occurrence of hyperemesis gravidarum is linked to smoking.

Hyperemesis gravidarum is a severe form of nausea and vomiting that affects around 1% of pregnancies. It is usually experienced between 8 and 12 weeks of pregnancy but can persist up to 20 weeks. The condition is thought to be related to raised beta hCG levels and is more common in women who are obese, nulliparous, or have multiple pregnancies, trophoblastic disease, or hyperthyroidism. Smoking is associated with a decreased incidence of hyperemesis.

The Royal College of Obstetricians and Gynaecologists recommend that a woman must have a 5% pre-pregnancy weight loss, dehydration, and electrolyte imbalance before a diagnosis of hyperemesis gravidarum can be made. Validated scoring systems such as the Pregnancy-Unique Quantification of Emesis (PUQE) score can be used to classify the severity of NVP.

Management of hyperemesis gravidarum involves using antihistamines as a first-line treatment, with oral cyclizine or oral promethazine being recommended by Clinical Knowledge Summaries. Oral prochlorperazine is an alternative, while ondansetron and metoclopramide may be used as second-line treatments. Ginger and P6 (wrist) acupressure can be tried, but there is little evidence of benefit. Admission may be needed for IV hydration.

Complications of hyperemesis gravidarum can include Wernicke’s encephalopathy, Mallory-Weiss tear, central pontine myelinolysis, acute tubular necrosis, and fetal growth restriction, preterm birth, and cleft lip/palate (if ondansetron is used during the first trimester). The NICE Clinical Knowledge Summaries recommend considering admission if a woman is unable to keep down liquids or oral antiemetics, has ketonuria and/or weight loss (greater than 5% of body weight), or has a confirmed or suspected comorbidity that may be adversely affected by nausea and vomiting.

Understanding Postpartum Depression

Postpartum depression is a common condition that affects many new mothers. It typically occurs within a year of childbirth and is characterized by a range of symptoms, including feelings of sadness, anxiety, and hopelessness. While some women may experience a short-lived reaction known as the baby blues, postnatal depression typically begins within two to three months of giving birth and can last for several months or even longer.

If you are experiencing symptoms of postpartum depression, it is important to seek help from a healthcare professional. Treatment options may include therapy, medication, or a combination of both. With the right support and treatment, it is possible to overcome postpartum depression and enjoy a healthy, happy life with your new baby.

No additional contraception is necessary if the Kyleena® IUS is inserted within the first seven days of a patient’s menstrual cycle. This form of intrauterine contraception contains a lower dose of levonorgestrel than the Mirena® IUS and is approved for use for up to five years.

New intrauterine contraceptive devices include the Jaydess® IUS and Kyleena® IUS. The Jaydess® IUS is licensed for 3 years and has a smaller frame, narrower inserter tube, and less levonorgestrel than the Mirena® coil. The Kyleena® IUS has 19.5mg LNG, is smaller than the Mirena®, and is licensed for 5 years. Both result in lower serum levels of LNG, but the rate of amenorrhoea is less with Kyleena® compared to Mirena®.

Missed Birth Control Pills

When it comes to missed birth control pills, most of the advice and evidence is based on studies of the 35 mcg oestrogen combined pill. However, it’s important to note that the risk of pregnancy with a missed 20 mcg pill may be higher than with a larger dose pill. Despite this, the Royal College of Obstetricians and Gynaecologists (RCOG) recommends that women take the missed pill and continue with the pack. Additional contraception is not required in this case.

If two or more pills are missed, it’s recommended to use barrier contraception for around seven days. It’s important to follow the instructions provided with your specific type of birth control pill and to speak with your healthcare provider if you have any concerns or questions.

Mastitis is a common condition that affects breastfeeding women, typically occurring six weeks after giving birth. It can be difficult to distinguish between an engorged breast, blocked duct, non-infectious mastitis, and infected mastitis. Milk accumulation in breast tissue can cause an inflammatory response, leading to bacterial growth and resulting in a painful breast with fever, malaise, and a tender, red, swollen, and hard area of the breast.

If symptoms do not improve or worsen after 12-24 hours despite effective milk removal, or if a nipple fissure is infected, infectious mastitis should be suspected. Breast milk culture is not routinely required unless mastitis is severe, there has been no response to antibiotics, or this is recurrent mastitis.

Management of mastitis involves relieving pain with simple analgesia and warm compresses, and ensuring complete emptying of the breast after feeding. Breastfeeding should be continued as it improves milk removal and prevents nipple damage. If pain prevents breastfeeding, expressing breast milk by hand or pump is recommended until breastfeeding can be resumed.

Antibiotics are only recommended if necessary, and the first line antibiotic is flucloxacillin for 14 days (erythromycin if penicillin allergic). Intravenous antibiotics are rarely needed, but urgent referral to breast surgeons for drainage may be necessary if a breast abscess is suspected.

Breastfeeding Problems and Management

Breastfeeding can come with its own set of challenges, but most of them can be managed with proper care and attention. Some common issues include frequent feeding, nipple pain, blocked ducts, and nipple candidiasis. These problems can be addressed by seeking advice on positioning, breast massage, and using appropriate creams and suspensions.

Mastitis is a more serious condition that affects around 1 in 10 breastfeeding women. It is important to seek treatment if symptoms persist or worsen, including systemic illness, nipple fissures, or infection. The first-line antibiotic is flucloxacillin, and breastfeeding or expressing should continue during treatment. If left untreated, mastitis can lead to a breast abscess, which requires incision and drainage.

Breast engorgement is another common issue that can cause pain and discomfort. It usually occurs in the first few days after birth and can affect both breasts. Hand expression of milk can help relieve the discomfort of engorgement, and complications can be avoided by addressing the issue promptly.

Raynaud’s disease of the nipple is a less common but still significant problem that can cause pain and blanching of the nipple. Treatment options include minimizing exposure to cold, using heat packs, avoiding caffeine and smoking, and considering oral nifedipine.

Concerns about poor infant weight gain can also arise, prompting consideration of the above breastfeeding problems and an expert review of feeding. Monitoring of weight until weight gain is satisfactory is also recommended. With proper management and support, most breastfeeding problems can be overcome, allowing for a successful and rewarding breastfeeding experience.

The patient should be informed that their future fertility is not impacted by the abortion and there is no association with placenta praevia, ectopic pregnancy, stillborn or miscarriage. However, they should also be made aware of the potential complications that may arise from the procedure. These include severe bleeding, uterine perforation (surgical abortion only), and cervical trauma (surgical abortion only). The risks of these complications are lower for early abortions and those performed by experienced clinicians. In the event that one of these complications occurs, further treatment such as blood transfusion, laparoscopy or laparotomy may be required. Additionally, infection may occur after medical or surgical abortion, but this risk can be reduced through prophylactic antibiotic use and bacterial screening for lower genital tract infection.

Termination of Pregnancy in the UK

The UK’s current abortion law is based on the 1967 Abortion Act, which was amended in 1990 to reduce the upper limit for termination from 28 weeks to 24 weeks gestation. To perform an abortion, two registered medical practitioners must sign a legal document, although in emergencies, only one is needed. The procedure must be carried out by a registered medical practitioner in an NHS hospital or licensed premise. The method used to terminate pregnancy depends on the gestation period. For pregnancies less than nine weeks, mifepristone followed by prostaglandins is used, while surgical dilation and suction of uterine contents are used for pregnancies less than 13 weeks. For pregnancies more than 15 weeks, surgical dilation and evacuation of uterine contents or late medical abortion is used. The 1967 Abortion Act outlines the conditions under which a person shall not be guilty of an offense under the law relating to abortion. These limits do not apply in cases where it is necessary to save the life of the woman, there is evidence of extreme fetal abnormality, or there is a risk of serious physical or mental injury to the woman.

Gestational diabetes can be identified through a fasting glucose level of 5.6 mmol/L or higher, or a 2-hour glucose level of 7.8 mmol/L or higher.

This particular woman is at risk of gestational diabetes due to her body mass index being over 30 kg/m². She has been diagnosed with gestational diabetes as her 2-hour glucose level is 7.8 mmol/L or higher, even though her fasting glucose level is within normal range.

It’s worth noting that impaired glucose tolerance is a term used for non-pregnant patients who have a 2-hour glucose level between 7.8mmol/L and 11.1mmol/L.

In this case, the woman’s 2-hour glucose level is elevated, indicating gestational diabetes, while her fasting glucose level is normal. These results are not considered normal.

Gestational diabetes is a common medical disorder that affects around 4% of pregnancies. It can develop during pregnancy or be a pre-existing condition. According to NICE, 87.5% of cases are gestational diabetes, 7.5% are type 1 diabetes, and 5% are type 2 diabetes. Risk factors for gestational diabetes include a BMI of > 30 kg/m², previous gestational diabetes, a family history of diabetes, and family origin with a high prevalence of diabetes. Screening for gestational diabetes involves an oral glucose tolerance test (OGTT), which should be performed as soon as possible after booking and at 24-28 weeks if the first test is normal.

To diagnose gestational diabetes, NICE recommends using the following thresholds: fasting glucose is >= 5.6 mmol/L or 2-hour glucose is >= 7.8 mmol/L. Newly diagnosed women should be seen in a joint diabetes and antenatal clinic within a week and taught about self-monitoring of blood glucose. Advice about diet and exercise should be given, and if glucose targets are not met within 1-2 weeks of altering diet/exercise, metformin should be started. If glucose targets are still not met, insulin should be added to the treatment plan.

For women with pre-existing diabetes, weight loss is recommended for those with a BMI of > 27 kg/m^2. Oral hypoglycaemic agents, apart from metformin, should be stopped, and insulin should be commenced. Folic acid 5 mg/day should be taken from preconception to 12 weeks gestation, and a detailed anomaly scan at 20 weeks, including four-chamber view of the heart and outflow tracts, should be performed. Tight glycaemic control reduces complication rates, and retinopathy should be treated as it can worsen during pregnancy.

Targets for self-monitoring of pregnant women with diabetes include a fasting glucose level of 5.3 mmol/l and a 1-hour or 2-hour glucose level after meals of 7.8 mmol/l or 6.4 mmol/l, respectively. It is important to manage gestational diabetes and pre-existing diabetes during pregnancy to reduce the risk of complications for both the mother and baby.

Before providing nicotine replacement therapy (NRT), it is recommended to conduct cognitive behavioral therapy (CBT) or motivational interviewing with pregnant women who smoke. Additionally, it is important to screen all pregnant women for smoking using a carbon monoxide monitor.

Smoking cessation is the process of quitting smoking. In 2008, NICE released guidance on how to manage smoking cessation. The guidance recommends that patients should be offered nicotine replacement therapy (NRT), varenicline or bupropion, and that clinicians should not favour one medication over another. These medications should be prescribed as part of a commitment to stop smoking on or before a particular date, and the prescription should only last until 2 weeks after the target stop date. If unsuccessful, a repeat prescription should not be offered within 6 months unless special circumstances have intervened. NRT can cause adverse effects such as nausea and vomiting, headaches, and flu-like symptoms. NICE recommends offering a combination of nicotine patches and another form of NRT to people who show a high level of dependence on nicotine or who have found single forms of NRT inadequate in the past.

Varenicline is a nicotinic receptor partial agonist that should be started 1 week before the patient’s target date to stop. The recommended course of treatment is 12 weeks, but patients should be monitored regularly and treatment only continued if not smoking. Varenicline has been shown in studies to be more effective than bupropion, but it should be used with caution in patients with a history of depression or self-harm. Nausea is the most common adverse effect, and varenicline is contraindicated in pregnancy and breastfeeding.

Bupropion is a norepinephrine and dopamine reuptake inhibitor, and nicotinic antagonist that should be started 1 to 2 weeks before the patient’s target date to stop. There is a small risk of seizures, and bupropion is contraindicated in epilepsy, pregnancy, and breastfeeding. Having an eating disorder is a relative contraindication.

In 2010, NICE recommended that all pregnant women should be tested for smoking using carbon monoxide detectors. All women who smoke, or have stopped smoking within the last 2 weeks, or those with a CO reading of 7 ppm or above should be referred to NHS Stop Smoking Services. The first-line interventions in pregnancy should be cognitive behaviour therapy, motivational interviewing, or structured self-help and support from NHS Stop Smoking Services. The evidence for the use of NRT in pregnancy is mixed, but it is often used if the above measures fail. There is no evidence that it affects the child’s birthweight. Pregnant women

Safe Medications for Hypertension in Pregnancy

Beta blockers are considered safe during the third trimester of pregnancy, but they are not commonly used due to concerns about intrauterine growth retardation. Instead, labetalol is often preferred as it has an established track record of safety and efficacy. Magnesium sulphate is a recognized treatment for pre-eclampsia, a condition not mentioned in this context. ACE inhibitors are not recommended for use during pregnancy. Nifedipine may be used as a second-line treatment. Methyldopa is a well-studied medication that has been shown to be both effective and safe for both mother and baby during pregnancy. By carefully selecting the appropriate medication, hypertension in pregnancy can be managed safely and effectively.

When it comes to treating infertility in PCOS, clomifene is usually the first choice. Metformin can also be used, but only after anti-oestrogens like clomifene have been tried.

Managing Polycystic Ovarian Syndrome

Polycystic ovarian syndrome (PCOS) is a condition that affects a significant percentage of women of reproductive age. Its management is complex due to the unclear cause of the condition. However, it is known that PCOS is associated with high levels of luteinizing hormone and hyperinsulinemia, and there is some overlap with the metabolic syndrome. General management includes weight reduction if appropriate and the use of combined oral contraceptives (COC) to regulate the menstrual cycle and induce a monthly bleed.

Hirsutism and acne are common symptoms of PCOS, and a COC pill may be used to manage them. Third-generation COCs with fewer androgenic effects or co-cyprindiol with an anti-androgen action are possible options. If these do not work, topical eflornithine may be tried, or spironolactone, flutamide, and finasteride may be used under specialist supervision.

Infertility is another issue that women with PCOS may face. Weight reduction is recommended if appropriate, and the management of infertility should be supervised by a specialist. There is an ongoing debate about whether metformin, clomifene, or a combination should be used to stimulate ovulation. A 2007 trial published in the New England Journal of Medicine suggested that clomifene was the most effective treatment. However, there is a potential risk of multiple pregnancies with anti-oestrogen therapies such as clomifene. The RCOG published an opinion paper in 2008 and concluded that on current evidence, metformin is not a first-line treatment of choice in the management of PCOS. Metformin is also used, either combined with clomifene or alone, particularly in patients who are obese. Gonadotrophins may also be used.

Cervical Screening During Pregnancy

According to the latest guidelines from the NHS Cervical Screening Programme, it is not recommended for women to have cervical screening while pregnant. However, if a smear test is due during pregnancy, it is advised to wait approximately three months after delivery before having the test. This recommendation is particularly relevant for women with no history of abnormal smears. It is important to follow these guidelines to ensure accurate results and to avoid any potential harm to the developing fetus. Therefore, if you are pregnant and due for a smear test, it is best to wait until after delivery to schedule your appointment.

Cardiac arrest cannot be listed as the sole cause of death on a death certificate as it is a method of dying and requires further clarification.

While the use of old age is discouraged, it may be listed on a death certificate for patients over the age of 80 if specific criteria are met (refer to the provided link).

The only acceptable abbreviations for HIV and AIDS should be used on a death certificate.

Death Certification in the UK

There are no legal definitions of death in the UK, but guidelines exist to verify it. According to the current guidance, a doctor or other qualified personnel should verify death, and nurse practitioners may verify but not certify it. After a patient has died, a doctor needs to complete a medical certificate of cause of death (MCCD). However, there is a list of circumstances in which a doctor should notify the Coroner before completing the MCCD.

When completing the MCCD, it is important to note that old age as 1a is only acceptable if the patient was at least 80 years old. Natural causes is not acceptable, and organ failure can only be used if the disease or condition that led to the organ failure is specified. Abbreviations should be avoided, except for HIV and AIDS.

Once the MCCD is completed, the family takes it to the local Registrar of Births, Deaths, and Marriages office to register the death. If the Registrar decides that the death doesn’t need reporting to the Coroner, he/she will issue a certificate for Burial or Cremation and a certificate of Registration of Death for Social Security purposes. Copies of the Death Register are also available upon request, which banks and insurance companies expect to see. If the family wants the burial to be outside of England, an Out of England Order is needed from the coroner.

The use of Warfarin during breastfeeding is deemed to be safe.

Breastfeeding Contraindications: Drugs and Other Factors to Consider

Breastfeeding is generally recommended for infants as it provides numerous benefits for both the baby and the mother. However, there are certain situations where breastfeeding may not be advisable. One of the major contraindications is the use of certain drugs by the mother, which can be harmful to the baby. Antibiotics like penicillins and cephalosporins, as well as endocrine medications like levothyroxine, can be given to breastfeeding mothers. On the other hand, drugs like ciprofloxacin, tetracycline, and benzodiazepines should be avoided.

Aside from drugs, other factors like galactosaemia and viral infections can also make breastfeeding inadvisable. In the case of HIV, some doctors believe that the benefits of breastfeeding outweigh the risk of transmission, especially in areas where infant mortality and morbidity rates are high.

It is important for healthcare professionals to be aware of these contraindications and to provide appropriate guidance to mothers who are considering breastfeeding. By doing so, they can help ensure the health and well-being of both the mother and the baby.

Understanding Infertility: Initial Investigations and Key Counselling Points

Infertility is a common issue that affects approximately 1 in 7 couples. However, it is important to note that around 84% of couples who have regular sex will conceive within 1 year, and 92% within 2 years. The causes of infertility can vary, with male factor accounting for 30%, unexplained causes accounting for 20%, ovulation failure accounting for 20%, tubal damage accounting for 15%, and other causes accounting for the remaining 15%.

To determine the cause of infertility, basic investigations are typically conducted. These include a semen analysis and a serum progesterone test, which is done 7 days prior to the expected next period. The interpretation of the serum progesterone level is as follows: if the level is less than 16 nmol/l, it should be repeated and if it consistently remains low, referral to a specialist is necessary. If the level is between 16-30 nmol/l, it should be repeated, and if it is greater than 30 nmol/l, it indicates ovulation.

In addition to these investigations, there are key counselling points that should be addressed. These include advising the patient to take folic acid, aiming for a BMI between 20-25, and having regular sexual intercourse every 2 to 3 days. Patients should also be advised to quit smoking and limit alcohol consumption.

By understanding the initial investigations and key counselling points for infertility, healthcare professionals can provide their patients with the necessary information and support to help them conceive.

Depo-provera is linked to an increase in weight.

As the woman is concerned about weight gain, it is not recommended for her to use depo-provera, which is the primary injectable contraceptive in the UK. This contraceptive can cause various adverse effects, including weight gain, irregular bleeding, delayed return to fertility, and an increased risk of osteoporosis.

Although some users of the combined oral contraceptive pill have reported weight gain, a Cochrane review doesn’t support a causal relationship between the pill and weight gain. Therefore, there are no contraindications for this woman to use the combined oral contraceptive pill.

The progestogen-only pill has not been associated with weight gain, and there are no contraindications for its use in this woman.

The intra-uterine system (IUS) is not linked to weight gain in users, and there are no contraindications for its use in this woman.

The subdermal contraceptive implant can cause irregular or heavy bleeding, as well as progestogen effects such as headaches, nausea, and breast pain. However, it doesn’t typically cause weight gain, and there are no contraindications for its use in this situation.

Injectable Contraceptives: Depo Provera

Injectable contraceptives are a popular form of birth control in the UK, with Depo Provera being the main option available. This contraceptive contains 150 mg of medroxyprogesterone acetate and is administered via intramuscular injection every 12 weeks. It can be given up to 14 weeks after the last dose without the need for extra precautions. The primary method of action is by inhibiting ovulation, while secondary effects include cervical mucous thickening and endometrial thinning.

However, there are some disadvantages to using Depo Provera. Once the injection is given, it cannot be reversed, and there may be a delayed return to fertility of up to 12 months. Adverse effects may include irregular bleeding and weight gain, and there is a potential increased risk of osteoporosis. It should only be used in adolescents if no other method of contraception is suitable.

It is important to note that Noristerat, another injectable contraceptive licensed in the UK, is rarely used in clinical practice. It is given every 8 weeks. The BNF gives different advice regarding the interval between injections, stating that a pregnancy test should be done if the interval is greater than 12 weeks and 5 days. However, this is not commonly adhered to in the family planning community.

During pregnancy, there is an increase in the levels of thyroxine-binding globulin (TBG), which causes an increase in the levels of total thyroxine. However, this doesn’t affect the free thyroxine level. If left untreated, thyrotoxicosis can increase the risk of fetal loss, maternal heart failure, and premature labor. Graves’ disease is the most common cause of thyrotoxicosis during pregnancy, but transient gestational hyperthyroidism can also occur due to the activation of the TSH receptor by HCG. Propylthiouracil has traditionally been the antithyroid drug of choice, but it is associated with an increased risk of severe hepatic injury. Therefore, NICE Clinical Knowledge Summaries recommend using propylthiouracil in the first trimester and switching to carbimazole in the second trimester. Maternal free thyroxine levels should be kept in the upper third of the normal reference range to avoid fetal hypothyroidism. Thyrotrophin receptor stimulating antibodies should be checked at 30-36 weeks gestation to determine the risk of neonatal thyroid problems. Block-and-replace regimens should not be used in pregnancy, and radioiodine therapy is contraindicated.

On the other hand, thyroxine is safe during pregnancy, and serum thyroid-stimulating hormone should be measured in each trimester and 6-8 weeks postpartum. Women require an increased dose of thyroxine during pregnancy, up to 50% as early as 4-6 weeks of pregnancy. Breastfeeding is safe while on thyroxine. It is important to manage thyroid problems during pregnancy to ensure the health of both the mother and the baby.

Chickenpox and Pregnancy

Chickenpox is a common illness that can affect pregnant women. It has an incubation period of 14 to 21 days and those affected are infectious for two days before the rash appears.

If the pregnant woman has a definite history of Chickenpox, there is no risk to the developing fetus. However, if there is uncertainty about past exposure, a blood test can be done to check for immunity.

If the test detects specific IgG, it confirms past exposure and the patient can be reassured. If not, VZ-immunoglobulin may be administered within 10 days from exposure to prevent infection.

If a pregnant woman who is not immune to Chickenpox is exposed to the virus, it is recommended to seek specialist advice. Varicella-zoster immunoglobulin (VZIG) can be effective in preventing Chickenpox if given within 10 days of exposure. However, in this scenario, the woman is already 16 weeks pregnant and aciclovir should only be given to women over 20 weeks gestation within 24 hours of rash onset. As the patient has already developed Chickenpox, VZIG would not be appropriate.

Chickenpox during pregnancy can lead to serious complications for both the mother and the fetus, including pneumonitis and fetal varicella syndrome (FVS) if contracted before 28 weeks gestation. Therefore, offering reassurance alone is not sufficient in this case. While there is no indication that the patient is unwell enough to require emergency care, appropriate safety-netting should be provided due to the risk of severe complications.

Chickenpox Exposure in Pregnancy: Risks and Management

Chickenpox is caused by the varicella-zoster virus and can pose risks to both the mother and fetus during pregnancy. The mother is at a five times greater risk of pneumonitis, while the fetus is at risk of developing fetal varicella syndrome (FVS) if the mother is exposed to Chickenpox before 20 weeks gestation. FVS can result in skin scarring, eye defects, limb hypoplasia, microcephaly, and learning disabilities. There is also a risk of shingles in infancy and severe neonatal varicella if the mother develops a rash between 5 days before and 2 days after birth.

To manage Chickenpox exposure in pregnancy, post-exposure prophylaxis (PEP) may be necessary. If the pregnant woman is not immune to varicella, VZIG or antivirals may be given within 10 days of exposure. Waiting until days 7-14 is recommended to reduce the risk of developing clinical varicella. However, the decision on choice of PEP for women exposed from 20 weeks of pregnancy should take into account patient and health professional preference as well as the ability to offer and provide PEP in a timely manner.

If a pregnant woman develops Chickenpox, specialist advice should be sought. Oral aciclovir may be given if the pregnant woman is ≥ 20 weeks and presents within 24 hours of onset of the rash. However, caution should be exercised if the woman is < 20 weeks. Overall, managing Chickenpox exposure in pregnancy requires careful consideration of the risks and benefits to both the mother and fetus.

A cervical smear is not a diagnostic test and should only be conducted as a part of a screening program. An 18-year-old’s risk of cervical cancer is already low, and a normal vaginal examination can further reduce it.

If controlling bleeding is the goal, the combined oral contraceptive pill is more effective than the progesterone-only pill.

Implanon and Nexplanon are both subdermal contraceptive implants that slowly release the hormone etonogestrel to prevent ovulation and thicken cervical mucous. Nexplanon is an updated version of Implanon with a redesigned applicator to prevent deep insertions and is radiopaque for easier location. It is highly effective with a failure rate of 0.07/100 women-years and lasts for 3 years. It doesn’t contain estrogen, making it suitable for women with a history of thromboembolism or migraines. It can be inserted immediately after a termination of pregnancy. However, a trained professional is needed for insertion and removal, and additional contraception is required for the first 7 days if not inserted on days 1-5 of the menstrual cycle.

The main disadvantage of these implants is irregular and heavy bleeding, which can be managed with a co-prescription of the combined oral contraceptive pill. Other adverse effects include headache, nausea, and breast pain. Enzyme-inducing drugs may reduce the efficacy of Nexplanon, and women should switch to a different method or use additional contraception until 28 days after stopping the treatment. Contraindications include ischaemic heart disease/stroke, unexplained vaginal bleeding, past breast cancer, severe liver cirrhosis, and liver cancer. Breast cancer is a UKMEC 4 condition, meaning it represents an unacceptable risk if the contraceptive method is used.

Contraceptive Methods and Timing

The timing of contraceptive methods is crucial to their effectiveness. The copper-bearing intrauterine device can be used at any time during the menstrual cycle, as long as pregnancy has been reasonably excluded. It doesn’t require any additional contraception. However, if a woman starts taking the combined oral contraceptive pill on day six or later of her menstrual cycle, she needs to use additional contraception or avoid sexual intercourse for seven days. The same applies to the Mirena coil if it is inserted from day eight onwards of the menstrual cycle. The progesterone-only pill and implant also require additional contraception or avoidance of sexual intercourse if started from day six onwards of the menstrual cycle. It is important to understand the timing requirements of each contraceptive method to ensure their effectiveness in preventing pregnancy.

A fundamental comprehension of physiology is necessary to comprehend contraception, gynaecological disorders, and fertility issues, as progesterone is produced by the corpus luteum after ovulation, despite the AKT having limited inquiries about it.

Phases of the Menstrual Cycle

The menstrual cycle is a complex process that can be divided into four phases: menstruation, follicular phase, ovulation, and luteal phase. During the follicular phase, a number of follicles develop in the ovaries, with one follicle becoming dominant around the mid-follicular phase. At the same time, the endometrium undergoes proliferation. This phase is characterized by a rise in follicle-stimulating hormone (FSH), which results in the development of follicles that secrete oestradiol. When the egg has matured, it secretes enough oestradiol to trigger the acute release of luteinizing hormone (LH), which leads to ovulation.

During the luteal phase, the corpus luteum secretes progesterone, which causes the endometrium to change to a secretory lining. If fertilization doesn’t occur, the corpus luteum will degenerate, and progesterone levels will fall. Oestradiol levels also rise again during the luteal phase. Cervical mucous thickens and forms a plug across the external os following menstruation. Just prior to ovulation, the mucous becomes clear, acellular, low viscosity, and stretchy. Under the influence of progesterone, it becomes thick, scant, and tacky. Basal body temperature falls prior to ovulation due to the influence of oestradiol and rises following ovulation in response to higher progesterone levels. Understanding the phases of the menstrual cycle is important for women’s health and fertility.

When women use an IUS for endometrial protection as part of their HRT regimen, they need to replace the device every 4 years according to the BNF or 5 years according to the FSRH. The Mirena® IUS is effective in protecting the endometrium from the effects of exogenous estrogen, and the BNF recommends its use for this purpose. However, if the Mirena® IUS is used for contraception and inserted after the age of 45, it can remain in place until menopause, even if the woman is still having periods.

Women over the age of 40 still require effective contraception until they reach menopause, despite a significant decline in fertility. The Faculty of Sexual and Reproductive Healthcare (FSRH) has produced specific guidance for this age group, titled Contraception for Women Aged Over 40 Years. No method of contraception is contraindicated by age alone, with all methods being UKMEC1 except for the combined oral contraceptive pill (UKMEC2 for women >= 40 years) and Depo-Provera (UKMEC2 for women > 45 years). The FSRH guidance provides specific considerations for each method, such as the use of COCP in the perimenopausal period to maintain bone mineral density and reduce menopausal symptoms. Depo-Provera use is associated with a small loss in bone mineral density, which is usually recovered after discontinuation. The FSRH also provides a table detailing how different methods may be stopped based on age and amenorrhea status. Hormone replacement therapy cannot be relied upon for contraception, and a separate method is needed. The FSRH advises that the POP may be used in conjunction with HRT as long as the HRT has a progestogen component, while the IUS is licensed to provide the progestogen component of HRT.

Extra precautions are not necessary when taking antibiotics with the progestogen-only pill.

Counselling for Women Considering the Progestogen-Only Pill

Women who are considering taking the progestogen-only pill (POP) should receive counselling on various aspects of the medication. One of the most common potential adverse effects is irregular vaginal bleeding. It is important to note that the POP should be taken at the same time every day, without a pill-free break, unlike the combined oral contraceptive (COC).

When starting the POP, immediate protection is provided if commenced up to and including day 5 of the cycle. If started later, additional contraceptive methods such as condoms should be used for the first 2 days. If switching from a COC, immediate protection is provided if continued directly from the end of a pill packet.

In case of missed pills, if the delay is less than 3 hours, the pill should be taken as usual. If the delay is more than 3 hours, the missed pill should be taken as soon as possible, and extra precautions such as condoms should be used until pill taking has been re-established for 48 hours.

It is important to note that antibiotics have no effect on the POP, unless the antibiotic alters the P450 enzyme system. Liver enzyme inducers may reduce the effectiveness of the POP. In case of diarrhoea and vomiting, the POP should be continued, but it should be assumed that pills have been missed.

Finally, it is important to discuss sexually transmitted infections (STIs) with healthcare providers when considering the POP. By providing comprehensive counselling, women can make informed decisions about whether the POP is the right contraceptive choice for them.

Management of Lower Urinary Tract Infection

Guidance from SIGN1 recommends that in cases of lower urinary tract infection (UTI), a dipstick test is not necessary if typical symptoms are present. However, if minimal symptoms or signs are present, a dipstick test should be performed. If the test is positive for leukocytes and nitrites, treatment should be commenced. If it is negative, clinical judgement should be used to determine whether to offer empirical treatment and/or send a mid-stream urine (MSU) sample.

In cases where there are signs or symptoms of upper UTI infection, such as loin pain and systemic symptoms, admission should be considered. Non-pregnant women of any age with symptoms or signs of acute LUTI should be treated with a three-day course of trimethoprim or nitrofurantoin.

By following these guidelines, healthcare professionals can effectively manage lower UTIs and provide appropriate treatment to patients. Proper management can help prevent the spread of infection and improve patient outcomes.

Antiphospholipid Syndrome: A Cause of Recurrent Miscarriage

Antiphospholipid syndrome is a medical condition that can lead to recurrent miscarriage. It can also present as arterial or venous thrombosis, livedo reticularis rash, stroke, adrenal hemorrhage, migraine, myelitis, myocardial infarction, or multi-infarct dementia. Anticardiolipin antibodies may be found in patients with this syndrome. Venous thrombi occur more often if lupus anticoagulant is positive, while arterial thrombi occur if IgG or IgM antiphospholipid antibody are positive. Long-term warfarin is indicated for treatment.

Initially, it was believed that up to 30% of SLE sufferers had antiphospholipid syndrome. However, it is now thought that primary antiphospholipid syndrome is a separate entity consisting of a tendency to thrombosis, positive antiphospholipid antibodies, but the absence of clinical features of SLE. It is important to recognize and diagnose this syndrome early to prevent complications such as recurrent miscarriage and thrombosis.

Disorders of Sex Development: Common Conditions and Characteristics

Disorders of sex development refer to a group of conditions that affect the development of an individual’s reproductive system. The most common disorders are androgen insensitivity syndrome, 5-α reductase deficiency, male and female pseudohermaphroditism, and true hermaphroditism. Androgen insensitivity syndrome is an X-linked recessive condition that results in end-organ resistance to testosterone, causing genotypically male children to have a female phenotype. 5-α reductase deficiency, on the other hand, is an autosomal recessive condition that results in the inability of males to convert testosterone to dihydrotestosterone, leading to ambiguous genitalia in the newborn period. Male and female pseudohermaphroditism are conditions where individuals have testes or ovaries but external genitalia are female or male, respectively. Finally, true hermaphroditism is a very rare condition where both ovarian and testicular tissue are present. Understanding the characteristics of these conditions is crucial in providing appropriate medical care and support for affected individuals.